CSC
VRTX icon

Caldwell Sutter Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Caldwell Sutter Capital’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.4K Hold
21
– – ﹤0.01% 606
2026
Q1 		$9.38K Hold
21
– – ﹤0.01% 568
2025
Q4 		$9.52K Hold
21
– – ﹤0.01% 554
2025
Q3 		$8.22K Sell
21
-1
-5% -$418 ﹤0.01% 581
2025
Q2 		$9.79K Hold
22
– – ﹤0.01% 538
2025
Q1 		$10.7K Hold
22
– – 0.01% 531
2024
Q4 		$8.86K Hold
22
– – ﹤0.01% 566
2024
Q3 		$10.2K Hold
22
– – ﹤0.01% 552
2024
Q2 		$10.3K Hold
22
– – 0.01% 554
2024
Q1 		$9.2K Hold
22
– – ﹤0.01% 554
2023
Q4 		$8.95K Hold
22
– – ﹤0.01% 557
2023
Q3 		$7.65K Hold
22
– – ﹤0.01% 557
2023
Q2 		$7.74K Buy
22
+18
+450% +$6.07K ﹤0.01% 555
2023
Q1 		$1.26K Sell
4
-496
-99% -$149K ﹤0.01% 515
2022
Q4 		$144K Buy
+500
New +$152K 0.13% 127

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Caldwell Sutter Capital's VRTX Position: Q2 2026 in Review

Caldwell Sutter Capital held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 21 shares worth $10.4K. The position accounts for ﹤0.01% of the portfolio, ranked #606.

Caldwell Sutter Capital first reported a position in VRTX in Q4 2022 and has held it in 15 quarters since. The position peaked at $144K in Q4 2022. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Caldwell Sutter Capital held 21 shares of Vertex Pharmaceuticals worth $10.4K as of Q2 2026.
  • Caldwell Sutter Capital left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
  • Vertex Pharmaceuticals made up ﹤0.01% of Caldwell Sutter Capital's portfolio in Q2 2026, its #606 holding.
  • Caldwell Sutter Capital first reported a position in Vertex Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
  • Caldwell Sutter Capital's Vertex Pharmaceuticals position peaked at $144K in Q4 2022.
  • 1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Caldwell Sutter Capital's 13F filing for Q2 2026, filed 5 Aug 2026.